Literature DB >> 2380333

Thyroxine 5'-deiodinase in human anterior pituitary tumors.

Y Itagaki1, K Yoshida, H Ikeda, K Kaise, N Kaise, M Yamamoto, T Sakurada, K Yoshinaga.   

Abstract

The activity of T4 5'-monodeiodinase (5'D) in the pituitary was measured in 12 patients with pituitary adenoma (3 patients with acromegaly, 2 with prolactinoma, 1 with Cushing's disease, 1 with TSH-producing tumor, and 5 with nonfunctioning tumor) and, as a control, in a patient who died of parotid cancer. The pituitaries, obtained at operation or autopsy, were homogenized in 0.1 mol/L potassium phosphate buffer, pH 7.0, and centrifuged at 800 x g. Supernatants were incubated with [125I]T4 and 20 mmol/L dithiothreitol (DTT) at 37C for 90 min. T4 5'-D was measured by the release of 125I- with the ion exchange method. The activity of T4 5'-D in the pituitaries from patients with prolactinoma and parotid cancer was dependent on protein concentration, incubation time, incubation temperature, and T4 concentration, and was labile to prior heating at 70 C for 30 min. T4 5'-D was not inhibited by 1 mmol/L propylthiouracil, but was inhibited 95% by 0.1 mmol/L iopanoic acid. The apparent Km and maximum velocity for T4 5'-D in homogenates of prolactinoma at 20 mmol/L DTT were 11 nmol/L and 1.54 pmol/mg protein.h, respectively. This reaction followed sequential-type reaction kinetics when the DTT concentration was varied. All other homogenates of pituitary tumors, except two nonfunctioning tumors, also demonstrated T4 5'-D activity. These results indicate that 1) the human pituitary express a low Km and PTU-insensitive T4 5'-D activity which is very similar to the type II enzyme activity in the rat pituitary; and 2) various types of pituitary tumor cells contain T4 5'-D activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2380333     DOI: 10.1210/jcem-71-2-340

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Type 2 iodothyronine deiodinase is highly expressed in human thyroid.

Authors:  D Salvatore; H Tu; J W Harney; P R Larsen
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

Review 2.  Iodothyronine deiodinases and cancer.

Authors:  A Piekiełko-Witkowska; A Nauman
Journal:  J Endocrinol Invest       Date:  2011-05-27       Impact factor: 4.256

3.  The evaluation of hypothalamic somatostatin tone using pyridostigmine and thyrotropin releasing hormone in patients with acromegaly.

Authors:  K Hanew; A Utsumi; A Sugawara; Y Shimizu; H Ikeda; K Abe
Journal:  J Endocrinol Invest       Date:  1994-05       Impact factor: 4.256

Review 4.  Deiodinases and Cancer.

Authors:  Annarita Nappi; Maria Angela De Stefano; Monica Dentice; Domenico Salvatore
Journal:  Endocrinology       Date:  2021-04-01       Impact factor: 4.736

5.  Essential Role of GATA2 in the Negative Regulation of Type 2 Deiodinase Gene by Liganded Thyroid Hormone Receptor β2 in Thyrotroph.

Authors:  Hideyuki Matsunaga; Shigekazu Sasaki; Shingo Suzuki; Akio Matsushita; Hirotoshi Nakamura; Hiroko Misawa Nakamura; Naoko Hirahara; Go Kuroda; Hiroyuki Iwaki; Kenji Ohba; Hiroshi Morita; Yutaka Oki; Takafumi Suda
Journal:  PLoS One       Date:  2015-11-16       Impact factor: 3.240

6.  The rs225017 polymorphism in the 3'UTR of the human DIO2 gene is associated with increased insulin resistance.

Authors:  Leonardo B Leiria; José M Dora; Simone M Wajner; Aline A F Estivalet; Daisy Crispim; Ana Luiza Maia
Journal:  PLoS One       Date:  2014-08-08       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.